Nivolumab is a drug which blocks a protein, called the programmed death-1 (PD-1) receptor, on thesurface of certain immune cells (called T-cells). By blocking the PD-1 receptor this triggers the T-cellsto find and kill cancer cells. Nivolumab is given as a drip directly into a vein in the hand or arm. Studiesof nivolumab in this population are currently being conducted to determine if it may extend survivalor slow the progression of the disease.
Nivolumab (Opdivo) for Oesophageal Cancer

Interventions:
Nivolumab (Opdivo; BMS-936558; ONO-4538)
Indications:
Oesophageal cancer
Therapeutic Areas:
Head and Neck Cancer
Year:
2017